Atherosclerosis Drug Market 2027 by Drug, Distribution Channel and Geography | The Insight Partners

Atherosclerosis Drug Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Drug Class (Cholesterol Lowering Medications, Angiotensin-Converting Enzyme (ACE) Inhibitors, Anti-platelet Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Calcium Channel Blockers, Diuretics, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online-pharmacies) and Geography

Report Code: TIPRE00008225 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Atherosclerosis is a condition in which arteries become narrow, enlarged, or they become hardened. These conditions lead to weak pulse rate, lowered blood pressure in limbs, and others. Therefore, to treat atherosclerosis conditions medications such as cholesterol medications, antiplatelet medications, beta-blocker medications, and others. These medications are known as atherosclerosis drugs.

MARKET DYNAMICS

The atherosclerosis drug market is projected to mark a good market value owing to the key driving factors such as rising incidences of atherosclerosis diseases, growing geriatric population, increasing pharmaceutical productions, and others. The market is expected to experience growth opportunities due to growing drug development activities, and rising market consolidations in the industry.

MARKET SCOPE

The "Global Atherosclerosis Drug Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of atherosclerosis drug market with detailed market segmentation by drug class, distribution, channel and geography. The global atherosclerosis drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading atherosclerosis drug market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global atherosclerosis drug market is segmented on the basis of drug class and application. Based on the drug class the market is categorized as cholesterol lowering medications, angiotensin-converting enzyme (ace) inhibitors, anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, calcium channel blockers, diuretics, and others. On the basis of distribution channel the market is segmented as hospital pharmacies, retail pharmacies, and online-pharmacies.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global atherosclerosis drug market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The atherosclerosis drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting atherosclerosis drug market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the atherosclerosis drug market in these regions.



Get more information on this report :

MARKET PLAYERS


The reports cover key developments in the atherosclerosis drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from atherosclerosis drug market are anticipated to lucrative growth opportunities in the future with the rising demand for atherosclerosis drug market in the global market. Below mentioned is the list of few companies engaged in the atherosclerosis drug market.

The report also includes the profiles of key atherosclerosis drug market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Mylan N.V.
  •  Sanofi S.A.
  •  AstraZeneca
  •  GlaxoSmithKline Plc
  •  Amgen
  •  Pfizer Inc.
  •  Janssen Pharmaceuticals, Inc. (Johnson and Johnson Services Inc.)
  •  Merck and Co., Inc.
  •  Novartis AG
  •  Bayer AG

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Atherosclerosis Drug Market - By Drug Class
1.3.2 Atherosclerosis Drug Market - By Distribution Channel
1.3.3 Atherosclerosis Drug Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. ATHEROSCLEROSIS DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. ATHEROSCLEROSIS DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. ATHEROSCLEROSIS DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. ATHEROSCLEROSIS DRUG - GLOBAL MARKET OVERVIEW
6.2. ATHEROSCLEROSIS DRUG - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. ATHEROSCLEROSIS DRUG MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. CHOLESTEROL LOWERING MEDICATIONS
7.3.1. Overview
7.3.2. Cholesterol Lowering Medications Market Forecast and Analysis
7.4. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
7.4.1. Overview
7.4.2. Angiotensin-Converting Enzyme (ACE) Inhibitors Market Forecast and Analysis
7.5. ANTI-PLATELET MEDICATIONS
7.5.1. Overview
7.5.2. Anti-platelet Medications Market Forecast and Analysis
7.6. FIBRIC ACID AND OMEGA-3 FATTY ACID DERIVATIVES
7.6.1. Overview
7.6.2. Fibric Acid and Omega-3 Fatty Acid Derivatives Market Forecast and Analysis
7.7. CALCIUM CHANNEL BLOCKERS
7.7.1. Overview
7.7.2. Calcium Channel Blockers Market Forecast and Analysis
7.8. DIURETICS
7.8.1. Overview
7.8.2. Diuretics Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis

8. ATHEROSCLEROSIS DRUG MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE-PHARMACIES
8.5.1. Overview
8.5.2. Online-pharmacies Market Forecast and Analysis

9. ATHEROSCLEROSIS DRUG MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Atherosclerosis Drug Market Overview
9.1.2 North America Atherosclerosis Drug Market Forecasts and Analysis
9.1.3 North America Atherosclerosis Drug Market Forecasts and Analysis - By Drug Class
9.1.4 North America Atherosclerosis Drug Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Atherosclerosis Drug Market Forecasts and Analysis - By Countries
9.1.5.1 United States Atherosclerosis Drug Market
9.1.5.1.1 United States Atherosclerosis Drug Market by Drug Class
9.1.5.1.2 United States Atherosclerosis Drug Market by Distribution Channel
9.1.5.2 Canada Atherosclerosis Drug Market
9.1.5.2.1 Canada Atherosclerosis Drug Market by Drug Class
9.1.5.2.2 Canada Atherosclerosis Drug Market by Distribution Channel
9.1.5.3 Mexico Atherosclerosis Drug Market
9.1.5.3.1 Mexico Atherosclerosis Drug Market by Drug Class
9.1.5.3.2 Mexico Atherosclerosis Drug Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Atherosclerosis Drug Market Overview
9.2.2 Europe Atherosclerosis Drug Market Forecasts and Analysis
9.2.3 Europe Atherosclerosis Drug Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Atherosclerosis Drug Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Atherosclerosis Drug Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Atherosclerosis Drug Market
9.2.5.1.1 Germany Atherosclerosis Drug Market by Drug Class
9.2.5.1.2 Germany Atherosclerosis Drug Market by Distribution Channel
9.2.5.2 France Atherosclerosis Drug Market
9.2.5.2.1 France Atherosclerosis Drug Market by Drug Class
9.2.5.2.2 France Atherosclerosis Drug Market by Distribution Channel
9.2.5.3 Italy Atherosclerosis Drug Market
9.2.5.3.1 Italy Atherosclerosis Drug Market by Drug Class
9.2.5.3.2 Italy Atherosclerosis Drug Market by Distribution Channel
9.2.5.4 Spain Atherosclerosis Drug Market
9.2.5.4.1 Spain Atherosclerosis Drug Market by Drug Class
9.2.5.4.2 Spain Atherosclerosis Drug Market by Distribution Channel
9.2.5.5 United Kingdom Atherosclerosis Drug Market
9.2.5.5.1 United Kingdom Atherosclerosis Drug Market by Drug Class
9.2.5.5.2 United Kingdom Atherosclerosis Drug Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Atherosclerosis Drug Market Overview
9.3.2 Asia-Pacific Atherosclerosis Drug Market Forecasts and Analysis
9.3.3 Asia-Pacific Atherosclerosis Drug Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Atherosclerosis Drug Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Atherosclerosis Drug Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Atherosclerosis Drug Market
9.3.5.1.1 Australia Atherosclerosis Drug Market by Drug Class
9.3.5.1.2 Australia Atherosclerosis Drug Market by Distribution Channel
9.3.5.2 China Atherosclerosis Drug Market
9.3.5.2.1 China Atherosclerosis Drug Market by Drug Class
9.3.5.2.2 China Atherosclerosis Drug Market by Distribution Channel
9.3.5.3 India Atherosclerosis Drug Market
9.3.5.3.1 India Atherosclerosis Drug Market by Drug Class
9.3.5.3.2 India Atherosclerosis Drug Market by Distribution Channel
9.3.5.4 Japan Atherosclerosis Drug Market
9.3.5.4.1 Japan Atherosclerosis Drug Market by Drug Class
9.3.5.4.2 Japan Atherosclerosis Drug Market by Distribution Channel
9.3.5.5 South Korea Atherosclerosis Drug Market
9.3.5.5.1 South Korea Atherosclerosis Drug Market by Drug Class
9.3.5.5.2 South Korea Atherosclerosis Drug Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Atherosclerosis Drug Market Overview
9.4.2 Middle East and Africa Atherosclerosis Drug Market Forecasts and Analysis
9.4.3 Middle East and Africa Atherosclerosis Drug Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Atherosclerosis Drug Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Atherosclerosis Drug Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Atherosclerosis Drug Market
9.4.5.1.1 South Africa Atherosclerosis Drug Market by Drug Class
9.4.5.1.2 South Africa Atherosclerosis Drug Market by Distribution Channel
9.4.5.2 Saudi Arabia Atherosclerosis Drug Market
9.4.5.2.1 Saudi Arabia Atherosclerosis Drug Market by Drug Class
9.4.5.2.2 Saudi Arabia Atherosclerosis Drug Market by Distribution Channel
9.4.5.3 U.A.E Atherosclerosis Drug Market
9.4.5.3.1 U.A.E Atherosclerosis Drug Market by Drug Class
9.4.5.3.2 U.A.E Atherosclerosis Drug Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Atherosclerosis Drug Market Overview
9.5.2 South and Central America Atherosclerosis Drug Market Forecasts and Analysis
9.5.3 South and Central America Atherosclerosis Drug Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Atherosclerosis Drug Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Atherosclerosis Drug Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Atherosclerosis Drug Market
9.5.5.1.1 Brazil Atherosclerosis Drug Market by Drug Class
9.5.5.1.2 Brazil Atherosclerosis Drug Market by Distribution Channel
9.5.5.2 Argentina Atherosclerosis Drug Market
9.5.5.2.1 Argentina Atherosclerosis Drug Market by Drug Class
9.5.5.2.2 Argentina Atherosclerosis Drug Market by Distribution Channel

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. ATHEROSCLEROSIS DRUG MARKET, KEY COMPANY PROFILES
11.1. MYLAN N.V.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SANOFI S.A.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. ASTRAZENECA
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GLAXOSMITHKLINE PLC
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. AMGEN
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. PFIZER INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. JANSSEN PHARMACEUTICALS, INC. (JOHNSON AND JOHNSON SERVICES INC.)
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MERCK AND CO., INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. NOVARTIS AG
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. BAYER AG
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Mylan N.V.
2. Sanofi S.A.
3. AstraZeneca
4. GlaxoSmithKline Plc
5. Amgen
6. Pfizer Inc.
7. Janssen Pharmaceuticals, Inc. (Johnson and Johnson Services Inc.)
8. Merck and Co., Inc.
9. Novartis AG
10. Bayer AG
TIPRE00008225
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking